Drug Profile

7MW 4911

Alternative Names: 7MW-4911

Latest Information Update: 09 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mabwell (Shanghai) Bioscience
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

30 Apr 2025 Mabwell plans to submit an IND application to the US FDA in H2 2025
30 Apr 2025 Mabwell plans to submit an IND application to the NMPA in H2 2025
30 Apr 2025 Adverse events, pharmacodynamics and pharmacokinetics data from a preclinical trials in Solid tumours released byMabwell Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com